Pharmafile.com’s weekly COVID-19 news round-up
pharmafile | April 7, 2021 | News story | Research and Development | COVID-19, COVID-19 vaccine, covid 19 news, covid-19 news, pharma, pharma news
The past week has seen plenty of COVID-19 vaccine news; AstraZeneca has halted the paediatric trial of their jab amid fear over blood clots, while Valneva’s new vaccine candidate advances to a Phase III trial, and the Pfizer-BioNTech shot has proven to remain 91.3% effective after six months.
1. AstraZeneca halt paediatric trial of COVID-19 vaccine amid blood clot probe – Published 07/04/2021
AstraZeneca has halted the trial of its COVID-19 vaccine on children aged between 6 and 17, while regulators investigate a possible link with the vaccine to rare blood-clot events in adults.
2. Valneva’s inactivated COVID-19 vaccine candidate advances to Phase III trial – Published 06/04/21
Specialty vaccine company Valneva’s inactivated COVID-19 jab has shown positive results in a Phase I/II trial, with a seroconversion rate of 100% in participants that received a high dose.
3. Pfizer vaccine 91.3% effective after six months, Phase III study shows – Published 06/04/21
Pfizer and BioNTech’s follow-up study of their COVID-19 vaccine has confirmed the jab’s high efficacy after up to six months, with an effectiveness of 91.3% against the virus.
4. BD’s rapid COVID-19 test granted Emergency Use Authorization by FDA – Published – 01/04/21
The FDA has granted Emergency Use Authorization (EUA) for Becton, Dickinson and Company’s (BD) rapid antigen test to be used for COVID-19 screening of asymptomatic individuals.
5. Celonic to manufacture at least 100 million CureVac COVID-19 jabs – Published 31/03/21
Celonic are to manufacture more than 100 million doses of CureVac’s COVID-19 vaccine, with 50 million shots expected to be produced before the end of this year.
Jack Goddard
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
COVID-19 vaccine eligibility creates challenges for UK pharmacies
Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …
